Peptide Biologix
Compound index
The atlas

Triptorelin ([D-Trp6]-LHRH)

Triptorelin is a synthetic decapeptide superagonist of gonadotropin-releasing hormone (GnRH / LHRH) in which the native achiral Gly6 residue is substituted with D-tryptophan (D-Trp6), conferring 50- to 100-fold greater pituitary GnRHR potency and resistance to hypothalamic/pituitary endopeptidases.

Engraved study of a small branching coral skeleton with fine surface ridges
Plate 36Triptorelin
Class V — Reproductive, Neurohypophyseal & Melanocortin Peptides
AA Sequence (Decapeptide) pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2
Regulatory & Compounding Status (April 2026)

Triptorelin pamoate is an FDA-approved prescription medication (marketed as Trelstar, Triptodur, and Decapeptyl). This monograph documents analytical, chromatographic, and receptor pharmacology reference specifications strictly for in vitro and preclinical laboratory research.

Molecular Properties

Parameter Specification
Chemical Name Triptorelin Acetate / [D-Trp6]-LHRH
Amino Acid Sequence pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2
Molecular Formula C64H82N18O13 (free base)
Molecular Weight 1311.45 g/mol (1311.47 g/mol free base; 1431.55 g/mol acetate salt)
CAS Number 57773-63-4 (free base); 140194-24-7 (acetate)
Chain Length 10 amino acids
Structure Type Linear decapeptide with N-terminal pyroglutamic acid, D-Trp6 substitution, and C-terminal amide

Physical Properties

Property Value / Range
Appearance White to off-white lyophilized powder
Solubility (Water) Soluble (≥2 mg/mL in sterile water)
Solubility (Buffer) Soluble in 0.9% NaCl, PBS, DMSO, and dilute acetic acid (≥1 mg/mL)
pH Range (1 mg/mL) 5.0–6.5 (reconstituted in water)
Stability (Lyophilized) Stable for 36 months at -20°C, protected from light and moisture
Stability (Reconstituted) 14–21 days at 4°C; 3–6 months at -20°C (single-use aliquots)

Analytical Specifications

Test Parameter Method Acceptance Criteria
Purity RP-HPLC (C18 column, 220 nm) ≥98.0%
Molecular Identity ESI-MS or MALDI-TOF MS [M+H]+ = 1311.47 ± 0.5 Da
Peptide Content Amino Acid Analysis / Nitrogen Content ≥95%
Endotoxin Level LAL Assay (USP <85>) <1.0 EU/mg
Acetate Content Ion Chromatography 8–12% (acetate salt)
TFA Content Ion Chromatography ≤0.1%
Water Content Karl Fischer Titration ≤6%

Storage Parameters

  • Long-term Storage: -20°C or -80°C in sealed vials under inert gas (nitrogen or argon)
  • Short-term Storage: 2–8°C for up to 1 month (lyophilized form)
  • Reconstituted Solution: Store at 4°C for up to 2 weeks or aliquot and freeze at -20°C (avoid repeated freeze-thaw cycles)
  • Protection: Shield from light exposure (contains two Trp residues sensitive to photo-oxidation) and moisture
  • Container: Amber glass or low-binding polypropylene vials recommended

In Vitro & Preclinical Model Concentrations

Literature summary of published study doses, routes, and schedules.
Application Concentration / Protocol Route / Media
In Vitro Pituitary Culture 0.1–10 nM (0.13–13 ng/mL) Direct addition to culture media
Rodent Models (Acute Flare) 50–500 μg/kg body weight (single dose) Subcutaneous (SC) or Intraperitoneal (IP)
Receptor Desensitization 100–200 μg/kg daily for 7–28 days Subcutaneous (SC)
Gonadal Suppression Models 0.5–2 mg/kg (depot formulation, monthly) Intramuscular (IM)

Laboratory Solvent Preparation: Dissolve in sterile water, 0.9% NaCl, or bacteriostatic water at 1 mg/mL; dilute in sterile PBS or culture media for working solutions.

Key Research Studies

Literature summary of published study doses, routes, and schedules.
Year Study Focus Key Findings
1982 Superagonist potency characterization D-Trp6 substitution increased GnRHR binding affinity 50–100 fold vs. native GnRH; demonstrated EC50 of 0.01–0.05 nM for LH release from rat pituitary cells
1995 Pharmacokinetics and receptor dynamics Single SC dose (100 μg/kg) produced initial LH surge at 4h followed by sustained suppression for 14–28 days; receptor downregulation detected by day 7 with >80% reduction in GnRHR density
2004 Depot formulation development Biodegradable microsphere depot released triptorelin over 1–3 months; maintained therapeutic suppression with single injection; plasma levels 0.5–2 ng/mL sustained gonadal axis suppression
2012 Structure-activity and metabolic stability D-amino acid at position 6 conferred peptidase resistance; plasma half-life extended to 3–5 hours vs. 2–4 minutes for native GnRH; metabolic stability increased 50–100 fold

Mechanism of Action

  • Receptor Binding: High-affinity superagonist at pituitary gonadotropin-releasing hormone receptors (GnRHR, Kd ~0.1–0.5 nM; 50–100x higher affinity than native GnRH).
  • Initial Agonist Effect ("Flare"): First 2–7 days: supraphysiological GnRHR activation triggers an LH/FSH surge and transient increase in sex steroids.
  • Receptor Downregulation: Continuous GnRHR stimulation induces receptor internalization and degradation, producing a 70–90% reduction in receptor density by day 14.
  • Gonadal Suppression: Sustained receptor desensitization leads to loss of pulsatile LH/FSH secretion and a hypogonadal state.
  • Half-Life: Plasma elimination half-life of 3–5 hours (SC) compared to 2–4 minutes for native gonadorelin; depot formulations provide sustained release over weeks to months.

Comparative Analysis: Triptorelin vs. Native GnRH

Parameter Native GnRH (Gonadorelin) Triptorelin ([D-Trp6]-GnRH)
Position 6 Amino Acid Gly (L-amino acid) D-Trp (D-amino acid)
Receptor Affinity (Kd) 1–5 nM 0.1–0.5 nM (50–100x higher)
Half-Life (SC) 2–4 minutes 3–5 hours (75–150x longer)
Potency (LH release EC50) 0.5–2 nM 0.01–0.05 nM (50–200x more potent)
Primary Effect Pulsatile stimulation Biphasic: initial surge then suppression

Quality Control Parameters

Test Method Acceptance Criteria
Appearance (visual) White to off-white powder; no discoloration
Chiral Purity (D-Trp6) D-isomer ≥99%; L-isomer <1% at position 6
RP-HPLC (purity) Main peak ≥98.0%; no single impurity >0.5%
ESI-MS (identity) [M+H]+ = 1311.47 ± 0.5 Da confirmed
Biological Activity ≥90% potency vs. reference standard in LH release assay

Primary Scientific References

  1. Engel JB, Schally AV. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab. 2007;3(2):157-167. PubMed: 17237843
  2. National Center for Biotechnology Information. PubChem Compound Summary for Triptorelin. PubChem: Triptorelin
  3. Limonta P, Marelli MM, Mai S, Motta M, Martini L, Moretti RM. GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies. Endocr Rev. 2012;33(5):784-811. PMC3461332